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Prevention of chronic kidney and vascular disease: Toward
global health equity—The Bellagio 2004 Declaration. Chronic
kidney disease (CKD) not only reflects target organ injury in
systemic vascular disease in the general population and in as-
sociation with diabetes, hypertension, and smoking, but it is
recognized as one of the major risk factors in the pathogen-
esis and outcome of cardiovascular disease. Recent surveys
have revealed that the prevalence of CKD, particularly the hid-
den mild form (mildly elevated levels of serum creatinine or
urinary albumin excretion), is surprisingly high in the general
population.
In recent years, the global epidemic of type 2 diabetes has led
to an alarming increase in the number of patients with CKD.
Most patients with CKD (over 50 million individuals world-
wide) succumb to cardiovascular events, while each year over
1 million develop end-stage renal failure, which requires costly
treatment and in many countries of the world, unaffordable
renal replacement therapy by chronic dialysis or renal trans-
plantation.
Alarmed by the immense challenge to human morbidity and
the economic burden of CKD and ensuing systemic cardiovas-
cular disease, the International Society of Nephrology convened
a multidisciplinary group of expert physicians and public health
leaders from around the world to develop strategies to delay and
avert this bleak future by effective prevention of CKD based
on awareness, early detection, and effective treatment.
Key words: chronic kidney disease, diabetes, hypertension, prevention,
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Chronic kidney diseases (CKD) are emerging as a
worldwide public health problem. In recent decades, we
have seen a shift in the major cause of death and disability
from nutritional deficiency and infectious diseases toward
noncommunicable diseases, with the highest mortality
caused by cardiovascular diseases (CVD). The growing
prevalence of CKD is one aspect of this shift. The cause
of the rise of CKD appears not to be due to intrinsic re-
nal disease (which actually shows a decline) but to the
dramatic rise in systemic diseases that damage the kid-
ney, such as generalized atherosclerotic disease and type
2 diabetes. Type 2 diabetes, in particular, is emerging as a
medical catastrophe of worldwide proportion [1], with its
devastating systemic vascular effects affecting, amongst
other organs, the kidneys. Kidney damage is not just a
threat to kidney function per se, but more importantly, it
is a major determinant for the development of progres-
sive severe atherosclerosis, ischemic vascular disease, and
cardiovascular death [2, 3]. In 2003, the close link between
CKD and CVD prompted the American Heart Associa-
tion to publish a statement recommending that patients
with CKD be considered as members of the highest risk
group for subsequent CVD events [4].
CKD is a major contributor to the health and socioeco-
nomic consequences of the global rise in diabetes-related
disease. Most diabetic patients with renal symptoms, un-
less adequately treated, will follow a path of vascular
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Table 1. A call to action for chronic kidney disease
Capacity-building of trained staff and infrastructure
Development of multidisciplinary integrated centres for research and
clinical care
Endorsement and support by national government and world health
bodies like World Health Organization
Support from pharmaceutical and corporate sectors and availability of
low-cost therapy
Regular Internet access for education and data collection
Establishment of regional surveillance and intervention studies
Education of primary care physicians and allied health professionals
Intensive, focused collaboration of medical specialty societies
incidents leading to cardiac death. Those who avoid car-
diac disease will develop end-stage renal failure (ESRF)
requiring renal replacement therapy (RRT).
When available and affordable, RRT by chronic dial-
ysis or renal transplantation is life saving but highly ex-
pensive and generally remains a temporary solution. In
low-income countries, where the increase of diabetes is
most alarming, RRT is too expensive and unavailable
for more than 95% of all patients who develop ESRF
[5]. In industrialized countries, the economic burden of
RRT will likely become unsustainable in the future. In
the United States, it is forecast that the overall cost for
RRT will have doubled in the next 10 years and will have
reached the staggering figure of US $30 billion per year,
absorbing a considerable proportion of the health care
budget [6].
Development of strategies for early detection and
prevention of kidney involvement is the only realistic
strategy to avert an imminent global health and eco-
nomic crisis and enhance equity in health care world-
wide. This was the main goal of the conference convened
in Bellagio, Italy, in March 2004 by the International
Society of Nephrology Commission for the Global Ad-
vancement of Nephrology. The strategies discussed at
the conference included improved gathering of biosta-
tistical and demographic data of CKD and establish-
ment of precise programs for early detection of CKD
as well as primary and secondary prevention. Such pro-
grams should be multidisciplinary and require strong
government, public, and health care commitment. The
scientific basis of these programs would assist in capacity-
building in medical science and cardiovascular, renal, and
diabetes care, which are crucial in providing the nec-
essary infrastructure, thus contributing to the enhance-
ment of health status and economic growth of poorer
nations.
NEW KNOWLEDGE FOR CKD IN DIABETES
AND CVD
It has been recognized for a long time that a significant
proportion (20%–40%) of all patients with both type 1
and 2 diabetes will develop kidney involvement charac-
terized by a progressive urinary loss of albumin and de-
teriorating creatinine clearance [7]. In the presence of
kidney involvement, diabetes—unless treated effect-
ively—runs a relentless course usually ending either in
premature cardiovascular events and death or ESRF re-
quiring RRT.
In these patients, the appearance of albumin in the
urine, first as microalbuminuria (between 30 and 300
mg/day) and later as macroalbuminuria (more than 300
mg/day) and nephrotic syndrome, is regarded as a sign
of generalized vascular dysfunction which, together with
hypertension, is an important component of the so-called
metabolic syndrome and a hallmark of future cardiovas-
cular and renal risk [8]. Albuminuria may also reflect
a rise in glomerular capillary pressure (glomerular hy-
pertension), as evidenced by functional and morphologic
studies in experimental models of diabetes, hypertension,
and CKD. These observations have been corroborated
in human clinical studies, where the reduction of sys-
temic and presumably glomerular hypertension had salu-
tary effects [9]. Glomerular hypertension is the result of
an imbalance in preglomerular and postglomerular vaso-
constriction mediated by an elevation of the intrarenal
renin-angiotensin system (RAS) [10]. Angiotensin II is
released into the circulation, raising systemic blood pres-
sure as well as inducing growth factors and inflammatory
processes in various tissues. This explains the highly ef-
fective correction of functional and structural changes
by angiotensin-converting enzyme and angiotensin II
receptor-blockade [11–14]. Glomerular albuminuria and
vascular dysfunction affect tubular cell function and peri-
tubular capillary circulation, respectively, which result in
a proinflammatory renal microenvironment culminating
in interstitial fibrosis and progressive loss of kidney func-
tion [15, 16].
Also, in patients with hypertension and in healthy in-
dividuals, microalbuminuria and macroalbuminuria have
been found to be associated with a strikingly elevated risk
for cardiovascular events. The level of blood pressure and
excessive albumin excretion can be reduced by drugs that
inhibit the RAS, thus lowering renal and cardiovascular
risk [17–19]. Genetic or racial factors modulating RAS,
low birth weight associated with a developmentally low
number of nephrons, and environmental factors may be
involved in susceptibility to CKD, and evidence for these
hypotheses is growing [9].
These findings indicate that kidney dysfunction and
albuminuria are important disease markers and play a
decisive role in the causation of clinically relevant dis-
ease in diabetes, hypertension, and even in the general
population as a whole. Recent studies have implied that
albuminuria can be used as a relatively simple and ef-
fective target of treatment with a much higher sensitivity
than systemic blood pressure, irrespective of racial back-
ground [20]. Long-term decrease in cardiovascular and
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renal events due to treatment shows a high correlation
with short-term reduction in albuminuria [21, 22]. Asso-
ciated reductions in systemic blood pressure are clearly
beneficial.
In a program aimed at early detection and primary pre-
vention of cardiovascular risk factors, we strongly ad-
vocate the inclusion of urinary albumin measurement
as the single most important determinant for diabetes-
associated clinically relevant disease. This is in line with
the recommendation of the National Kidney Foundation
and its Kidney Disease Outcome Quality Initiative, which
stresses the importance of screening susceptible individ-
uals and those at risk of CKD for albuminuria at regular
intervals [23].
CURRENT EPIDEMIOLOGY, BIOSTATISTICS,
DEMOGRAPHY, PROJECTIONS WITH COST
ESTIMATES
Worldwide, approximately 50 million individuals suffer
from progressive CKD, and more than 1 million people
are treated with RRT [6]. Of these, 85% live in industrial-
ized countries. The incidence of ESRF requiring RRT has
doubled over the past 15 years, with further doubling pre-
dicted in the next 10 years, largely due to the increasing
incidence of type 2 diabetes and obesity.
In 2001, the annual cost for RRT in the United States
was US $22.8 billion [24], a figure that may well double
in 10 years, in light of the steady rise in the number of pa-
tients requiring treatment. Currently, between 30% and
50% of all cases of ESRF in industrialized countries are
due to diabetes and hypertension. By contrast, in the de-
veloping world, a high proportion is still due to infection-
related kidney diseases but with a growing number of
diabetic and hypertensive vascular nephropathies caused
by changes in lifestyle.
World Health Organization (WHO) statistics revealed
that the annual death rate from intrinsic kidney and uri-
nary tract disease was 1 million in the year 2002, ranking
12th on the list of major causes of death [25]. CVD (in-
cluding diabetes and CKD) was responsible for 14 million
deaths and was listed as the leading cause. The preva-
lence of CKD in the community has been grossly un-
derestimated in the past. Recent surveys and population
studies have confirmed a high prevalence of CKD in the
community. For instance, in the United States, the Third
National Health and Nutrition Examination Survey es-
timated that around 11% of the population (19 million)
may have some degree of CKD [26]. Annually, 100,000
patients develop ESRF out of an estimated 19 million
with CKD. Of these, 8 million have significant renal insuf-
ficiency (glomerular filtration rate [GFR] <60 mL/min).
It is evident that most of these 8 million patients do not
have time to progress to ESRF, because they succumb to
cardiovascular side effects before they lose renal function
completely. From this, it can be calculated that a signifi-
cant proportion of the 14 million people who died in 2002
of CVD worldwide may have had some degree of CKD
that would have contributed to the outcome. Such a close
association between CVD and CKD highlights the signif-
icant benefit that can be gained from early detection and
treatment of CKD.
The same study suggested that a much higher num-
ber of individuals are at risk of developing CKD when
the number of patients with diabetes (15 million) and
hypertension (43 million) as well as relatives of patients
with CKD are taken into consideration. In The Nether-
lands, the Groningen Prevention of Renal and Vascular
End-stage Disease study revealed similar disturbing re-
sults, showing that the prevalence of microalbuminuria
is as high as 7% in the general population and is asso-
ciated with an increased cardiovascular risk [27, 28]. In
Australia, registry data show similar increases in diabetes
type 2, obesity, and CKD as in the United States and
Canada [29, 30]. The Australian Diabetes, Obesity and
Lifestyle Study, a nationwide community-based study of
11,247 adults, revealed that up to 16% of those tested
had some renal abnormalities, with around 7% having
albuminuria [31, 32]. In Australia, RRT is available for
650 per million population (pmp), as compared with 1100
pmp in the United States and 650 pmp in Western Europe.
In Eastern Europe, the prevalence of ESRF is 200 pmp,
and in Latin America it varies between 5 and 600 pmp
(average of 345 pmp) in direct correlation with national
income and health budget expenditure.
Data from Latin America reveal a striking increase in
obesity and type 2 diabetes over the past 5 years, which
reflects changes in food intake and lifestyle [33]. Similar
increases in the incidence and prevalence of type 2 di-
abetes have been documented in the indigenous Native
American populations in the United States [34], in the
Aborigines in Australia [35], and in India [36]. In India,
less than 5% of patients who develop ESRD can afford
some sort of RRT and of those who can, the majority
drop out within 6 months [5]. Unfortunately, this situa-
tion is prevalent in many, if not most, developing coun-
tries, where RRT is a luxury accessible only to a few.
Currently, there are more than 177 million people with
diabetes worldwide [37]. By 2030, this number will rise
to 360 million according to conservative estimates of the
WHO. Considering that at least 1 in 3 people will develop
CKD, it is clear that no country and no health care sys-
tem will be able to offer adequate RRT, and that early
detection and prevention are the only means of escape
from a scenario of inadequate and unequal distribution
of life-saving measures such as RRT.
Studies on cost effectiveness of tertiary prevention of
CKD by treatment of hypertension, albuminuria, and the
use of RAS inhibitors have revealed a marked and signif-
icant reduction in expenditure with an important gain in
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health and with fewer cardiovascular events [38, 39]. This
would be especially pertinent in targeted patient groups
with increased susceptibility to develop CKD [40]. In ad-
dition, a recent publication shows that early intervention
appears to be more cost effective than late intervention
[41].
Screening the normal population for signs of chronic
diseases such as hypertension, diabetes, and CKD char-
acterized by albuminuria or loss of GFR has been
studied little. In the Australian Diabetes, Obesity and
Lifestyle Study mentioned above [32], 75% of patients
with microalbuminuria or proteinuria had hypertension
and/or diabetes as the cause. Indeed, one third of the adult
population was at risk of CKD due to hypertension, di-
abetes, or smoking. Half of the patients who were found
to have diabetes or arterial hypertension were previously
undiagnosed. Thus, the prevalence of community-based
CKD is substantial and 50% remain undiagnosed.
An additional observation was the association of smok-
ing with CKD—even in those individuals without hy-
pertension or diabetes [31]. Again, this has important
ramifications for the developing world, where heavy
smoking is endemic.
The Groningen Prevention of Renal and Vascular End-
stage Disease study by De Jong et al screened for albu-
minuria in a representative cohort of 90,000 inhabitants
of Groningen who were requested by mail to provide a
morning sample of urine. Of the more than 40,000 respon-
dents, no less than 16.6% had high normal albuminuria
(10 to 20 mg/L), and 7.2% had microalbuminuria (20–200
mg/L). Albuminuria was found to be strikingly related
to loss of GFR, increased cardiovascular events, and all
cause mortality during follow-up [42, 28]. Furthermore,
Asselberg et al recently showed [43] that intervention di-
rected at lowering albuminuria offers cardiac protection
beyond blood pressure control in the general healthy pop-
ulation, a finding previously reported in clinical trials in
patients with early and advanced diabetic and nondia-
betic proteinuric nephropathies.
In India, Mani showed highly successful early detection
and effective preventive treatment, with inexpensive and
readily available drugs, in a rural community in which
he screened a population of 25,000 for hypertension, di-
abetes, and CKD with the help of 6 social health officers
at a cost of less than US $6000 [44].
PREVENTION STRATEGIES
To avoid the devastating health and economic effects
of the diabetic vascular pandemic, worldwide action
is clearly needed to develop and implement preven-
tion strategies. As described previously, these have been
shown to be effective. Prevention strategies should be
aimed at: (1) detecting those at risk of developing CKD;
(2) preventing the onset of CKD in susceptible individ-
uals by altering lifestyle; (3) detecting those with early
stage CKD; (4) preventing progression of CKD by inter-
vention; (5) developing and applying diagnostic guide-
lines including albuminuria and estimated GFR as well
as therapeutic guidelines; (6) raising awareness with the
general public, policymakers, and physicians; and (7) cre-
ating funds and facilities for global assistance.
The recently published practice guidelines of the U.S.
National Kidney Foundation [23] and its use of albumin-
uria and other markers provide an excellent basis for
establishing prevention strategies. These guidelines ad-
vocate definition and staging of CKD, application of diag-
nostic markers, and assessment of concomitant morbidity.
The U.S. National Kidney Foundation recommends that
populations at risk for CKD (i.e., those with diabetes mel-
litus, hypertension, or family history of CKD) should be
screened for microalbuminuria at least annually.
To be successful in implementing prevention strate-
gies, awareness needs to be raised among public health
policymakers and health care workers. In Mexico, where
there is a particularly high and sharply rising prevalence
of diabetes mellitus, an educational program directed to
general and family practitioners working in the public
health system for the diagnosis and prevention of diabetic
nephropathy has recently been initiated. The program is
being applied to 25 geographic regions and involves a
nephrologist, trained in the program and in its objectives,
who works with 20 family physicians within 1 region. An
evaluation instrument is being developed and will be ap-
plied before and after the training.
Because the success of prevention of renal and cardio-
vascular chronic disease can only be measured after a
number of years and requires reliable statistics, a com-
bined and multidisciplinary effort will be required from
pertinent medical specialties (nephrology, cardiology, en-
docrinology, internal medicine, public health care) as well
as the WHO and other health care administrations to mo-
bilize public and national policymakers.
A CALL TO ACTION
Carefully designed and meticulously executed clini-
cal projects have to be implemented to generate reli-
able measures of health and economic gain. As such,
these projects will provide an important and vital basis
for capacity-building in preventive medicine, which is of
major importance for many emerging low- and middle-
income countries [45]. Industrialized countries have an
obligation to assist where needed in technical support, the
exchange of students and scholars, and in facilitating un-
hindered and continuous supply of diagnostics and thera-
peutics. The endorsement of WHO is invaluable, because
it will allow concerted, multidisciplinary action through
its existing networks. Support from the pharmaceutical
industry is likewise of prime importance [46], in that it
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has the ability to achieve effective primary and secondary
prevention and bring the world community closer to eq-
uity in health. Free internet access to full-text publications
is required to sustain the academic effort in building pre-
vention programs. Efforts should be made to increase
currently available access through the WHO-supported
Health InterNetwork Access to Research Initiative by
including more countries and reducing the per capita in-
come level currently applied [47]. These efforts can be
complemented by web-based educational networks [48].
The Bellagio participants are currently implementing 7 of
these multidisciplinary programs in South Africa, Cuba,
India, China, The Philippines, Mexico, Bolivia, Moldavia,
and Nigeria. The center for biostatistics and epidemiol-
ogy at the Mario Negri Institute in Bergamo, together
with the Institutes in Sheffield and Groningen, will pro-
vide, under the umbrella of the newly founded European
Kidney Institute, a surveillance center to collect demo-
graphic and biostatistical data from these studies. The
European Kidney Institute will also provide training op-
portunities for nephrologists from developing countries
in the field of public health and epidemiology of CKD re-
search. The International Society of Nephrology enjoys
strong collaboration with the International Federation of
Diabetes [49] and the International Society of Hyperten-
sion and aims at establishing coalitions with other spe-
cialty societies in order to optimize effectiveness. The In-
ternational Society of Nephrology and WHO continue
their joint commitment in realizing this mission.
Reprints requests to Professor Jan J. Weening, M.D., Academic Med-
ical Center, Department of Pathology, Meibergdreef 9, 1105 AZ Amster-
dam, The Netherlands.
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